Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Staar Warning Letter Presents Challenges For ICL Approval Timeline

This article was originally published in The Gray Sheet

Executive Summary

Staar Surgical continues to anticipate approval for the Collamer ICL implantable contact lens by April, despite compliance issues raised in a Dec. 22 FDA warning letter
Advertisement

Related Content

Staar Will Respond To FDA On “Serious, Continuing Violations”
Staar Will Respond To FDA On “Serious, Continuing Violations”
Staar Tackles Compliance Issues; AMO Sets Sights On Overseas Lens Market
Staar Tackles Compliance Issues; AMO Sets Sights On Overseas Lens Market
Staar Sets Sights On ICL Approval, Awaits Swiss, U.S. Facility Inspections
Staar Sets Sights On ICL Approval, Awaits Swiss, U.S. Facility Inspections
Staar warning letter progress
Ophtec Unfazed By FDA Panel Limitations On Phakic IOL Patient Group
Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003
Staar, Ophtec Address Panel’s Phakic IOL Endothelial Cell Loss Concerns
Advertisement
UsernamePublicRestriction

Register

MT019598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel